300942.SZ
易瑞生物
SZSE · Healthcare · C 制造业 · CN
CNY 6.98
+3.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 271.5M | 263.2M | 224.2M | 254.1M | 686.9M |
| Cost of Revenue | 96.8M | 94.8M | 65.9M | 127.2M | 298.8M |
| Gross Profit | 174.7M | 168.4M | 158.4M | 126.9M | 388.1M |
| Operating Expenses | |||||
| R&D Expense | 42.9M | 41.4M | 40.5M | 53.1M | 111.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 47.1M | 46.6M | 50.3M | 94.4M | 92.3M |
| Selling & Marketing Expense | 62.5M | 58.1M | 45.0M | 56.8M | 58.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 181.6M | 165.6M | 144.4M | 205.2M | 256.7M |
| Cost and Expenses | 278.4M | 260.4M | 210.3M | 332.4M | 555.5M |
| Operating Income (EBIT) | (2.5M) | 5.6M | 21.0M | (175.3M) | 98.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 5.2M | 13.3M | 19.7M | (177.8M) | 94.9M |
| Income Tax Expense | (4.0M) | (2.2M) | 3.1M | 7.2M | 12.2M |
| Bottom Line | |||||
| Net Income | 6.8M | 13.7M | 17.1M | (184.9M) | 83.0M |
| Earnings from Cont. Ops | 9.2M | 15.5M | 16.6M | (185.0M) | 82.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 6.8M | 13.7M | 17.1M | (184.9M) | 83.0M |
| Per Share | |||||
| Basic EPS | CN¥0.02 | CN¥0.03 | CN¥0.04 | (CN¥0.46) | CN¥0.21 |
| Diluted EPS | CN¥0.02 | CN¥0.03 | CN¥0.04 | (CN¥0.46) | CN¥0.21 |
| Revenue Per Share | CN¥0.67 | CN¥0.57 | CN¥0.52 | CN¥0.63 | CN¥1.74 |
| Shares | |||||
| Basic Shares Outstanding | 405.5M | 458.1M | 427.9M | 402.0M | 395.1M |
| Diluted Shares Outstanding | 405.5M | 458.1M | 427.9M | 402.0M | 395.1M |
| Profitability Metrics | |||||
| EBITDA | — | 36.2M | 36.3M | (143.9M) | 114.4M |
| D&A | — | 30.6M | 15.3M | 31.4M | 16.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026